Expertise in
3
conditions

Dr. David S. Poch

Pulmonary Medicine
Regents Of The University Of California
200 W Arbor Dr, 
San Diego, CA 
Offers Telehealth
Expertise in
3
conditions
Regents Of The University Of California
200 W Arbor Dr, 
San Diego, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Poch is a Pulmonary Medicine provider in San Diego, California. Dr. Poch is highly rated in 3 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Angioplasty, and Splenectomy.

His clinical research consists of co-authoring 32 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Licenses
Internal Medicine in CA
Hospital Affiliations
Uc San Diego Health Hillcrest - Hillcrest Med Ctr
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

REGENTS OF THE UNIVERSITY OF CALIFORNIA
200 W Arbor Dr, San Diego, CA 92103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
Enrollment Status: Completed
Publish Date: May 13, 2025
Intervention Type: Other, Drug
Study Drug: Sotatercept
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
Enrollment Status: Terminated
Publish Date: February 22, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
View 6 Less Clinical Trials

32 Total Publications

Tricuspid annular plane systolic excursion to pulmonary artery systolic pressure ratio in chronic thromboembolic pulmonary hypertension improves with balloon pulmonary angioplasty.
Tricuspid annular plane systolic excursion to pulmonary artery systolic pressure ratio in chronic thromboembolic pulmonary hypertension improves with balloon pulmonary angioplasty.
Journal: Pulmonary circulation
Published: July 25, 2024
Similar Doctors
George Z. Cheng
Expertise in
19
conditions
Dr. George Z. Cheng
Pulmonary Medicine | Intensive Care Medicine
Expertise in
19
conditions
Dr. George Z. Cheng
Pulmonary Medicine | Intensive Care Medicine

Regents Of The University Of California

200 W Arbor Dr, 
San Diego, CA 
 (0.1 mi)
858-249-6753
Experience:
16+ years
Languages Spoken:
English
Offers Telehealth

George Cheng is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in San Diego, California. Dr. Cheng has been practicing medicine for over 16 years is highly rated in 19 conditions, according to our data. His top areas of expertise are Pleural Effusion, Lung Nodules, Tracheobronchomalacia, Endoscopy, and Advanced Bronchoscopy.

Douglas J. Conrad
Expertise in
5
conditions
Dr. Douglas J. Conrad
Pulmonary Medicine
Expertise in
5
conditions
Dr. Douglas J. Conrad
Pulmonary Medicine

Regents Of The University Of California

200 W Arbor Dr, 
San Diego, CA 
 (0.1 mi)
858-657-7000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Douglas Conrad is a Pulmonary Medicine provider in San Diego, California. Dr. Conrad is highly rated in 5 conditions, according to our data. His top areas of expertise are Cystic Fibrosis, Secondary Immunodeficiency (SID), Newborn Jaundice, and Asthma.

Expertise in
2
conditions
Dr. Kim M. Kerr
Pulmonary Medicine | Intensive Care Medicine
Expertise in
2
conditions
Dr. Kim M. Kerr
Pulmonary Medicine | Intensive Care Medicine

Regents Of The University Of California

200 W Arbor Dr, 
San Diego, CA 
 (0.1 mi)
858-249-6753
Languages Spoken:
English
See accepted insurances

Kim Kerr is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in San Diego, California. Dr. Kerr is highly rated in 2 conditions, according to our data. Her top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Splenectomy, and Angioplasty.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Poch's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile